CURX News & Events

Curanex Pharmaceuticals has engaged Strategic Investor Relations, a premier investor relations firm, to enhance Curanex's visibility in the financial community and support its ongoing efforts to engage and educate current and potential investors about the Company's innovative pipeline and strategic initiatives. With this new partnership, Curanex aims to refine its communication strategies and investor relations activities to ensure stakeholders are fully informed and engaged with the Company's progress and prospects. Strategic Investor Relations will assist Curanex in highlighting its botanical drug development approach, which encompasses high-efficacy botanical drugs with de-risked clinical pathways and its positioning in the rapidly expanding botanical drug market.

Curanex Pharmaceuticals, a developmental stage pharmaceutical company focused on discovering and developing botanical drugs for inflammatory diseases, priced its initial public offering of 3.75M shares of common stock at a public offering price of $4.00 per share. The company intends to use the proceeds from the offering for the development of its lead product candidate, Phyto-N, for the treatment of ulcerative colitis; to conduct FDA-required good laboratory practice toxicology and pharmacokinetic studies for Phyto-N in ulcerative colitis, to prepare and submit an Investigational New Drug application, and for working capital and other general corporate purposes. Dominari Securities is acting as the lead underwriter for the offering.

Curanex Pharmaceuticals announced the pricing of its initial public offering of 3,750,000 shares of common stock at a public offering price of $4.00 per share, for gross proceeds of $15M, before deducting underwriting discounts and offering expenses. The Offering is being conducted on a firm commitment basis. The Company's shares of common stock are expected to begin trading on the Nasdaq Capital Market on August 26, 2025, under the ticker symbol "CURX." The Company has granted the underwriters an option, exercisable within 45 days from the close of the Offering, to purchase up to 562,500 additional shares of common stock at the public offering price, less underwriting discounts and expenses. The Offering is expected to close on August 27, 2025, subject to customary closing conditions. The Company intends to use the proceeds from the Offering for: the development of our lead product candidate, Phyto-N, for the treatment of ulcerative colitis; to conduct FDA-required good laboratory practice toxicology and pharmacokinetic studies for Phyto-N in ulcerative colitis, to prepare and submit an Investigational New Drug application, and for working capital and other general corporate purposes. Dominari Securities is acting as the lead underwriter for the Offering, with Pacific Century Securities and Revere Securities acting as co-underwriters.